Awakn

Awakn Life Sciences Corp. (OTC:AWKNF), a clinical-stage biotechnology company, has announced a new partnership with the University of Nottingham to conduct in vivo testing of its aminoindane new chemical entity as part of its preclinical program. This research will explore the therapeutic potential...

Awakn Life Sciences Corp. (OTCQB:AWKNF), a company focused on the development of psychedelic therapeutics for addiction and mental health disorders, has announced an increase in the size of its ongoing private placement financing. What Happened: Initially planned for $1 million, the offering has...

Since 2020, Awakn Life Sciences Corp. (OTCQB: AWKNF) reports that it has been researching, developing and commercializing therapeutics to treat addiction with a near-term focus on alcohol-use disorder (AUD). The company is undeniably doing important work - addiction remains one of the...

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. It’s arguably been an exciting few weeks for Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a Toronto-based biotechnology company...

This article by Freddie Earlam was originally published on Microdose and appears here with permission. If the industry-defining research already conducted at UK centers such as Imperial College, King’s college or even Exeter University’s recent Ketamine Research...

Picture credit: Martin Sanchez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The addiction treatment and rehabilitation industry in the United States alone is worth almost $40 billion...